Experts' consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases in China (2022)
成人血液病患者接种新型冠状病毒疫苗中国专家共识（2022年版）(151418)
Chinese guidelines for diagnosis and treatment of myelodysplastic syndromes (2019)
骨髓增生异常综合征中国诊断与治疗指南（2019年版）(125134)
Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)
成人原发免疫性血小板减少症诊断与治疗中国指南（2020年版）(99114)
Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021)
中国成人急性髓系白血病（非急性早幼粒细胞白血病）诊疗指南（2021年版）(91061)
Chinese guidelines for diagnosis and treatment of adult acute lymphoblastic leukemia (2021)
中国成人急性淋巴细胞白血病诊断与治疗指南（2021年版）(81057)
Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2020)
中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南（2020年版）(67390)
4.Editorial Peer-review Process
12.Data Sharing and Reproducibility
Chinese Journal of Hematology is published monthly in Chinese by the Chinese Medical Association, and is a peer reviewed medical journal for health management doctors, health researchers, and health workers in the field of health. The journal reports the advances and progress in current health sciences and technology.
Chinese Journal of Hematology was established in 1995, indexed by PMC, Pubmed, EM, AJ, WPRIM, CNKI, Wanfang Data, CSCD, etc. The impact factor of the journal is 1.283 in 2021, ranking the first among all hematology journals in China. The journal is available both in print and online.
Chinese Journal of Hematology covers all aspects of hematology, including disorders of leukocytes, both benign and malignant, erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. All articles undergo a rigorous peer-review and are selected on the basis of the originality of the findings, the superior quality of the work described, and the clarity of presentation.
All manuscripts must be submitted online through the website:
https://cmaes.medline.org.cn/Login/Login.aspx
First-time users will have to register at this site. Registration is free but mandatory. Registered authors can keep track of their articles after logging into the site using their username and password. Authors do not have to pay for submission of articles. If you experience any problems, please contact the editorial office by email:zhxyx@hematoline.com.
Manuscripts are reviewed for possible publication with the understanding that they are being submitted only to Chinese Journal of Hematology and have not been published, simultaneously submitted, or already accepted for publication elsewhere. The Editorial team may subject any manuscript submitted for consideration of publication in Chinese Journal of Hematology to plagiarism-detection software.
This does not preclude consideration of a manuscript that has been rejected by another journal or a complete report that follows publication of preliminary findings elsewhere, usually in the form of an abstract. Copies of any possibly duplicate published material should be submitted with the manuscript under consideration, with a statement in the cover letter as to why the manuscript currently being submitted is not a duplicate publication.
Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest.Authors without conflicts of interest, including relevant financial interests, activities, relationships, and affiliations, should indicate such in their disclosures and include a statement of no such interests in the Acknowledgment section of the manuscript. All sources of funding should be acknowledged in the manuscript. All relevant conflicts of interest and sources of funding should be included on the title page of the manuscript with the heading "Conflicts of Interest and Source of Funding:" For example: “Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is currently receiving a grant (#12345) from Organization Y, and is on the speaker's bureau for Organization X - the CME organizers for Company A. For the remaining authors, no relevant conflicts of interest were declared.”
A financial disclosure section is part of the submission process and must be completed by each author at submission. This information is for review by the Editors but will be published if relevant to the content of the accepted manuscript.
The primary purpose of the disclosure section is to determine whether authors have received any commercial financial support that could create a conflict of interest. In addition to monetary interests, a potential for conflict of interest can exist whether or not an individual believes that a relationship (such as dual commitments, competing interests, or competing loyalties) affects his or her scientific judgment. Please review ICMJE Uniform Requirements for Manuscripts.
When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national). If doubt exists whether the research was conducted in accordance with the ethical standards, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.
Our policy on research ethics is made to ensure that all articles published by Chinese Journal of Hematology report on work that is morally acceptable, and expects authors to follow the World Medical Association’s Declaration of Helsinki. To achieve this, we aim to appraise the ethical aspects of any submitted work that involves human participants, whatever descriptive label is given to that work including research, audit, and sometimes debate.
Research involving human participants, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption). Further information and documentation to support this should be made available to the Editor on request. Manuscripts may be rejected if the Editor considers that the research has not been carried out within an appropriate ethical framework. In rare cases, the Editor may contact the ethics committee for further information.
If a study has not been granted ethics committee approval prior to commencing, retrospective ethics approval usually cannot be obtained, and it may not be possible to consider the manuscript for peer review. The decision on whether to proceed to peer review in such cases is at the Editor's discretion.
Authors reporting the use of a new procedure or tool in a clinical setting, for example as a technical advance or case report, must give a clear justification in the manuscript for why the new procedure or tool was deemed more appropriate than usual clinical practice to meet the patient’s clinical need. Such justification is not required if the new procedure is already approved for clinical use at the authors’ institution. Authors will be expected to have obtained ethics committee approval and informed patient consent for any experimental use of a novel procedure or tool where a clear clinical advantage based on clinical need was not apparent before treatment.
For all research involving human participants, informed consent to participate in the study should be obtained from participants (or their parent or legal guardian in the case of children under 16) and a statement to this effect should appear in the manuscript. For manuscripts reporting studies involving vulnerable groups (for example, unconscious patients) where there is the potential for coercion (for example prisoners) or where consent may not have been fully informed, manuscripts will be considered at the editor’s discretion and may be referred to an internal editorial oversight group for further scrutiny. Consent must be obtained for all forms of personally identifiable data including biomedical, clinical, and biometric data. In the case of articles describing human transplantation studies, authors must include a statement declaring that no organs/tissues were obtained from prisoners and must also name the institution(s)/clinic(s)/department(s) via which organs/tissues were obtained. Documentary evidence of consent must be supplied if requested.
Chinese Journal of Hematology requires registration of clinical trials. Registration in the following trial registers is acceptable: http://www.chictr.org.cn/; http://www.clinicaltrials.gov/; http:// www.isrctn.org/; http://www.trialregister.nl/trialreg/index.asp; and http://www.umin.ac.jp/ctr and any registry that is a primary register of the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/network/primary/en/index.html).
We believe that editors have a duty to take on issues of unethical audit or research, not to seek punishment for the authors, but to prevent unethical practice and to protect patients.
If the Editor, with or without the advice of its ethics committee and/or COPE, considers the work in a submitted article to be ethically unsound the editor may seek further advice or recommend investigation or action. The fact that the article would have been rejected anyway for other scientific or editorial reasons would not prevent the editor from taking such further action on serious ethics problems.
There are differing definitions of scientific misconduct. We deal with these problems on a case by case basis while following guidance produced by bodies that include the Committee on Publication Ethics (COPE), the World Association of Medical Editors (WAME) and the International Committee of Medical Journal Editors (ICMJE).
After authors submit their manuscripts, we will detect them on academic misconduct. Firstly, we will detect the similarity of the paper via the manuscript review platform, and then, the system will automatically generate a detection report according to the "Criteria for the Definition of Misconduct in Academic Papers" of CNKI (powered by China Academic Journals (CD Edition)). Electronic Publishing House Co., Ltd) or “WANFANG Similarity Detection” (powered by WANFANG Data Co., Ltd.). If the manuscript’s replication ratio exceeds 20%, the Editor of the Journal may believe that there may be plagiarism.
If an editor has concerns that a submitted article describes something that might be considered to constitute misconduct in research, publication or professional behavior, we may discuss the case in confidence with committee.
If the case cannot be resolved by discussion with the author(s) and the Editor still has concerns, the case may be reported to the appropriate authorities. If, during the course of reviewing an article, an editor is alerted to possible problems (for example, fraudulent data) in another publication, the editor may contact the journal in which the previous publication appeared to raise concern.
Readers that suspect misconduct in a published article are encouraged to report this to the relevant journal editor and/or the Publisher for that title.
If the author has any objection to the decision of the manuscript, he can send email to: zhxyx, our officiawill deal with it in a timely manner.
A manuscript will be reviewed for possible publication with the understanding that it is being submitted to Chinese Journal of Hematology alone at that point in time and has not been published anywhere, simultaneously submitted, or already accepted for publication elsewhere. The journal expects that authors would authorize one of them to correspond with Chinese Journal of Hematology for all matters related to the manuscript. On submission, full-time editors review all submitted manuscripts initially for suitability for formal review. Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message are rejected before proceeding for formal peer-review. Manuscripts that are unlikely to be of interest to the journal readers are also liable to be rejected at this stage.
Manuscripts that are found suitable for publication in Chinese Journal of Hematology are sent to two or more expert reviewers. During submission, the contributor is requested to provide names of two or three qualified reviewers who have had experience in the subject of the submitted manuscript, but this is not mandatory. The reviewers should not be affiliated with the same institutes as the contributor(s). The selection of these reviewers is at the sole discretion of full-time editors. The journal follows a double-blind review process, wherein the reviewers and authors are unaware of each other’s identity. The journal holds a meeting monthly in Beijing or outside Beijing to make the final decision on whether or not to publish a manuscript, with the Chief Editor and editorial board members of the journal as attendees. The comments and suggestions (acceptance/rejection/amendments in manuscript) received from reviewers are conveyed to the corresponding author. If required, the author is requested to provide a point-by-point response to reviewers’ comments and submit a revised version of the manuscript. This process is repeated till reviewers and editors are satisfied with the manuscript.
Manuscripts accepted for publication are copy edited by full time editors in the editorial office. Page proofs are sent to the corresponding author. The corresponding author is expected to return the corrected proofs within several days. The whole process of submission of the manuscript to final decision and sending proofs is completed online.
Chinese Journal of Hematology should consider retracting a publication if:
Chinese Journal of Hematology abides by COPE Retraction Guidelines.
As stated in the International Committee of Medical Journal Editors (ICMJE) Recommendations, credit for authorship requires:
Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship. Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the content of the manuscript. The order of naming the contributors should be based on the relative contribution of the contributor towards the study and writing the manuscript. Once submitted the order cannot be changed without written consent of all the contributors. Manuscripts must be submitted by one of the authors, and should not be submitted by anyone on their behalf. The corresponding author takes responsibility for the article during submission and peer review.
Authors should determine the order of authorship among themselves and should settle any disagreements before submitting their manuscript. Changes in authorship (i.e., order, addition, and deletion of authors) should be discussed and approved by all authors. Any requests for such changes in authorship after initial manuscript submission and before publication should be explained in writing to the editor in a letter or email from all authors and should send the original signed written consent of all authors with authorized unit stamp.
Contributors should provide a description of contributions made by each of them towards the manuscript. Description should be divided in following categories, as applicable: concept, design, definition of intellectual content, literature search, health management studies, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing and manuscript review. One author should take responsibility for the integrity of the work as a whole from inception to published article and should be designated as ‘corresponding author’.
The general responsibilities of the editors of Chinese Journal of Hematology are listed below:
Decision on the Publication of Articles：The editors are responsible for deciding which of the articles submitted to Chinese Journal of Hematology should be published. The editors may be guided by the policies of the journal's editorial board subjected to such legal requirements regarding libel, copyright infringement and plagiarism. The editors may consult with reviewers in making this decision.
Manuscripts shall be evaluated solely on their intellectual merit.
The editors and any editorial staff must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher.
Disclosure and Conflicts of Interest：Unpublished materials disclosed in a submitted manuscript must not be used by anyone who has a view of the manuscript while handling it in his or her own research without the express written consent of the author.
The editors should not hold conflicts of interest with authors whose work they are assessing, e.g., if they are from the same institution or collaborate closely. In this case the chief editor or a suitable editorial board member will make final acceptance decisions for submitted papers.
The editors require skills of proofreading, copy editing, developmental editing, line editing and editing for search engine optimization.
It is the responsibility of the editor to reject a piece of writing that appears to be plagiarized or ghost written by another sub-editor. He should check that a particular piece is neither self-plagiarized, nor has been published before elsewhere.
The responsibilities of the reviewer of Chinese Journal of Hematology are summarized as follows:
The reviewer should provide an honest, critical assessment of the research. The reviewer should not manipulate the process to force the authors to address issues interesting or important to the reviewer but peripheral to the objective(s) of the study.
The reviewer should maintain confidentiality about the existence and substance of the manuscript. It is not appropriate to share the manuscript or to discuss it in detail with others or even to reveal the existence of the submission before publication.
The reviewer must not participate in plagiarism. It is obviously a very serious transgression to take data or novel concepts from a paper to advance your own work before the manuscript is published.
The reviewer should always avoid, or disclose, any conflicts of interest. For example, if the reviewer has a close personal or professional relationship with one or more of the authors such that his/her objectivity would be compromised. Scientific merit should be the basis for all reviews.
The reviewer should accept manuscripts for review only in his/her areas of expertise.
The reviewer should agree to review only those manuscripts that can be completed on time. Sometimes, unforeseen circumstances arise that preclude a reviewer from meeting a deadline, but in these instances the reviewer should immediately contact the editor.
The reviewer also has the unpleasant responsibility of reporting suspected duplicate publication, fraud, plagiarism, or ethical concerns about the use of animals or humans in the research being reported.
The reviewer should write reviews in a collegial, constructive manner. This is especially helpful to new investigators. No one likes to have a paper rejected, but a carefully worded review with appropriate suggestions for revision can be very helpful.
Manuscripts must be prepared in accordance with “ICMJE Recommendations”. The uniform requirements and specific requirement of Chinese Journal of Hematology are summarized below. Before submitting a manuscript, contributors are requested to check for the latest instructions available. Instructions are also available from the website of the Journaand from the manuscript submission site: http://cmaes.medline.org.cn.
Original article is required to provide a structured abstract with no more than 300 words. Other articles are required to provide indicative abstracts with less than 200 words.
It is the responsibility of authors/contributors to obtain permissions for reproducing any copyrighted material. A copy of the permission obtained must accompany the manuscript. Copies of any and all published articles or other manuscripts in preparation or submitted elsewhere that are related to the manuscript must also accompany the manuscript.
Editorials/commentaries are usually commissioned, however, unsolicited editorials/commentaries are also welcome. Editorials/commentaries can be up to 3000 words in length with no more than 30 references and with an indicative abstract less than 200 words.
Guidelines & Consensuses produced by professional medical society/association/group are reported in this kind of article, with an indicative abstract more than 400 words.
These mainly include randomized controlled trials, studies of screening and diagnostic test, outcome studies, cost effectiveness analyses, case-control series, and basic medical studies.
The text of original articles amounting to about 5000 words (excluding abstract, references and tables) should be divided into sections with the headings abstract, key words, introduction, methods, results, discussion, references.
Abstract: The abstract of original articles is a structured abstract, which includes the following four parts: objective, methods, results and conclusions. The total number words of abstract are no more than 400 words.
Key words: List 2-5 key words according to MeSH.
Introduction: State the purpose and summarize the rationale for the study or observation.
Methods: It should include and describe the following aspects:
Ethics: When reporting studies on human beings, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration. For prospective studies involving human participants, authors are expected to mention about approval of regional/ national/ institutional or independent Ethics Committee or Review Board, obtaining informed consent from adult research participants and obtaining assent for children aged over 7 years participating in the trial. The age beyond which assent would be required could vary as per regional and/ or national guidelines. Ensure confidentiality of subjects by desisting from mentioning participants’ names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the institution’s or a national research council’s guide for, or any national law on the care and use of laboratory animals was followed.
Evidence for approval by a local Ethics Committee (for both human as well as animal studies) must be supplied by the authors on demand. Animal experimental procedures should be as humane as possible and the details of anesthetics and analgesics used should be clearly stated. The ethical standards of experiments must be in accordance with the guidelines provided by the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Humans for studies involving experimental animals and human beings, respectively. The journal will not consider any paper which is ethically unacceptable. A statement on ethics committee permission and ethical practices must be included in all research articles under the ‘Methods’ section.
Study design: Describe your selection of the observational or experimental participants (patients or laboratory animals, including controls) clearly, including eligibility and exclusion criteria and a description of the source population.
Identify the methods, apparatus (give the manufacturer's name and address in parentheses), and procedures in sufficient detail to allow other workers to reproduce the results.
Give references to established methods, including statistical methods (see below); provide references and brief descriptions for methods that have been published but are not well known; describe new or substantially modified methods, give reasons for using them, and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration.
Reports of randomized clinical trials should present information on all major study elements, including the protocol, assignment of interventions (methods of randomization, concealment of allocation to treatment groups), and the method of masking (blinding), based on the CONSORT Statement.
Statistics: Quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Authors should report losses to observation (such as, dropouts from a clinical trial). When data are summarized in the Results section, specify the statistical methods used to analyze them. Specify the computer software used. P values are encouraged to be reported as the exact value or less than 0.05 or 0.01. Mean differences in continuous variables, proportions in categorical variables and relative risks including odds ratios and hazard ratios should be accompanied by their confidence intervals.
Results: Present your results in a logical sequence in the text, tables, and figures, giving the main or most important findings first. Do not repeat in the text all the data in the tables or figures; emphasize or summarize only important observations.
When data are summarized in the Results section, give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated, and specify the statistical methods used to analyze them. Restrict tables and figures to those needed to explain the argument of the paper and to assess its support. Use graphs as an alternative to tables with many entries; do not duplicate data in graphs and tables. Where scientifically appropriate, analyses of the data by variables such as age and sex should be included.
Discussion: Include summary of key findings (primary outcome measures, secondary outcome measures, results as they relate to a prior hypothesis); Strengths and limitations of the study (study question, study design, data collection, analysis and interpretation); Interpretation and implications in the context of the totality of evidence; Controversies raised by this study; and Future research directions (for this particular research collaboration, underlying mechanisms, clinical research).
Do not repeat in detail data or other material given in the Introduction or the Results section. In particular, contributors should avoid making statements on economic benefits and costs unless their manuscript includes economic data and analyses. Avoid claiming priority and alluding to work that has not been completed. New hypotheses may be stated if needed, however they should be clearly labeled as such. About 30 references can be included.
Only results of meta analysis are reported in this kind of article. The length of the article is about 5000 words (not including tables, figures, and references), with structured abstract no more than 400 words.
Special cases are reported in this kind of article. The length of the article is about 2000 words (not including tables, figures, and references). The text contains no abstract and key words.
These articles are usually commissioned, with about 5000 words in length (not including tables, figures, and references). The text contains no abstract and key words.
It is expected that these articles would be written by individuals who have done substantial work on the subject or are considered experts in the field. The prescribed word count is about 5000 words excluding tables, references and abstract. The manuscript may have about 100 references. The manuscript should have an indicative abstract (less than 200 words) representing an accurate summary of the article.
Personal views on controversial issues are welcome and the length should be about 2500 words (not including tables, figures, and references). The text contains no abstract and key words.
Minutes of an important meeting or other events are reported in this kind of article and the length should be about 2500 words (not including tables, figures, and references). The text contains no abstract and key words.
Letter to editors should preferably be related to articles previously published in the journal or views expressed in the journal. The text contains no abstract and key words, with five or fewer references, maximum of one table or one figure.
Authors are responsible for the accuracy and completeness of their references and for correct citation of the text. References should be numbered consecutively in the order in which they are first mentioned in the text (not in alphabetic order). Identify references in text, tables, and legends by Arabic numerals in superscript before the punctuation marks. References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or figure. The titles of journals should be abbreviated according to the style used in Index Medicus. Avoid using abstracts as references. Information from manuscripts submitted but not accepted should be cited in the text as “unpublished observations” with written permission from the source. Avoid citing a “personal communication” unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text.
The commonly cited types of references are shown here. Number references in the order they appear in the text; do not alphabetize. In text, tables, and legends, identify references with superscript Arabic numerals. When listing references, abbreviate titles of journals according to Medline.
Note: List authors and/or editors up to three; if more than three, list the first three authors followed by et al. From Jan. 2016, the available DOI should be added at the end of each reference.
Examples of journal citations
[1] Cui RR, Sun J, Li PF, et al. Secreted frizzled-related protein 1 gene polymorphisms and smoking in large artery atherosclerotic stroke[J]. Chin J Neurol, 2018, 51(1): 14-20. DOI: 10.3760/cma.j.issn.1006-7876.2018.01.004.
[2] Stadler S, Jalili S, Schreib A, et al. Association of sleep-disordered breathing with severe chronic vascular disease in patients with type 2 diabetes[J]. Sleep Med, 2018, 48: 53-60. DOI: 10.1016/j.sleep.2018.05.001.
Example of a book citation
[1] Murray PR, Rosenthal KS, Kobayashi GS, et al. Medical microbiology[M]. 4th ed. St. Louis: Mosby, 2002: 45-49.
[2] Weinstein L, Swartz MN. Pathogenic properties of invading microorganisms. In: Sodeman WA Jr., Sodeman WA, eds. Pathologic physiology: mechanisms of disease[M]. Philadelphia: Saunders, 1974: 457-472.
Example of electronic sources citation
[1] Jablonski S. Online multiple congenital anomaly/mental retardation (MCA/MR) syndromes [DB/OL]. Bethesda (MD): National Library of Medicine (US). 1999 (2001-11-20) [2002-12-12]. http: //www.nlm.nih.gov/mesh/jablonski/syndrome_title.html.
The Journal reserves the right to crop, rotate, reduce, or enlarge the photographs to an acceptable size.
Identifying information should not be published in written descriptions, photographs, sonograms, CT scans, etc., and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian, wherever applicable) gives written informed consent for publication. Authors should remove patients’ names from figures unless they have obtained written informed consent from the patients.
All right reserved by the Chinese Medical Association.
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
Authors have to pay an Article Processing Charge (APC) if the article is accepted for publication.
Authors from China: CNY 800 - 1500 per page (the number of pages is calculated based on the final PDF version), an additional fee maybe charged if figures need to be printed in color.
Authors outside China: USD 200 per print page including the cost of all figures (the number of pages is calculated based on the final PDF version).
The ways in which the journal and individual articles are available to readers by subscriptions or pay-per-view fees.
The journal's website will permanently preserve contents published at least from 1980. If readers find missing papers or inaccessible, please contact us.
The electronic copy of the journal is permanently preserved by the National Archives of Editions of China from 2022.
The journal supports the STM article sharing principles to enable research collaboration. Collaboration has always been essential to further research progress. In support of this The journal works with many commercial and non-commercial organizations providing services for the aggregation, posting, and sharing of journal articles.
The journal publishes advertisements in print, which are subject to the supervision and management of the Advertising Law of the People's Republic of China, and only can be read by special people after being reviewed by special persons. Any kind of misleading advertisements on paper shall be rejected.
The journal’s website does not publish any advertisement.
Any direct or indirect marketing activity involved in a manuscript shall be carefully considered and not accepted. The journal publishes only true and not misleading information to readers.
